ArticleThe American journal of tropical medicine and hygiene2024
Resurgence of Dengue Virus Serotype 2: Findings from the 2023 Bangladesh Outbreak.
Article in The American journal of tropical medicine and hygiene, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Epidemiological Characteristics of Dengue Infection in Bangladesh: A Systematic Review.International journal of environmental research and public health · 2026Pooled it
- Progression of dengue during an outbreak (2024) in Dhaka, Bangladesh: a hospital based longitudinal study.The Lancet regional health. Southeast Asia · 2026Article
- Dengue fatality, health seeking behavior and spatiotemporal dynamics in nonendemic regions of Bangladesh during the 2023 outbreak.Scientific reports · 2026Article
- The emergence of hyperendemic dengue in Bangladesh: An ecological study of structural breaks and transmission regime shifts, 2008-2025.PloS one · 2026Article
- Molecular xenosurveillance ofMicrobiology spectrum · 2025Article
- The Return of Chikungunya in Bangladesh in 2024: Implications for Future Outbreaks.The American journal of tropical medicine and hygiene · 2025Article
- Diagnostic accuracy of the OnSite Dengue Ag rapid test in symptomatic patients from Dhaka, Bangladesh.BMC infectious diseases · 2025Article
- Dengue virus detection in nasopharyngeal swabs among pediatric cases in Bangladesh.IJID regions · 2025Article
- Concurrent transmission of Zika virus during the 2023 dengue outbreak in Dhaka, Bangladesh.PLoS neglected tropical diseases · 2025Article
- NS1 Rapid Card Test for Dengue Detection: Insights from the 2023 Outbreak in Bangladesh.International journal of general medicine · 2025Article
- The major and minorGigaByte (Hong Kong, China) · 2025Article
- Spatio-temporal patterns of dengue in Bangladesh during 2019 to 2023: Implications for targeted control strategies.PLoS neglected tropical diseases · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bangladesh experienced the largest and deadliest dengue outbreak in 2023, after the virus had reappeared in the country 2 decades earlier. A total of 1,705 people died in Bangladesh, representing the highest case fatality rate (0.5%) due to dengue in the world for that year. The severity of dengue infection is to some extent related to the emergence of new circulating serotypes. To identify the possible predominant serotype in 2023, the reverse transcription polymerase chain reaction-based identification technique was used on stored serum samples of suspected dengue patients during the period between July and December 2023. The overall result of molecular serotyping showed that dengue virus (DENV-2) reappeared as the predominant serotype (74.1%), followed by a moderate number of samples with DENV-1 (19.8%) and DENV-3 (6.1%), in 2023. However, DENV-1 was found to be dominant in a few rural areas of Cox's Bazar districts. During the 2019 outbreak, DENV-3 was the dominant serotype, which seemed to be replaced by the DENV-2 serotype; this may have impacted the increased case fatality in 2023.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.